.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Prof. Dr. Andreas Meisel

Berlin / DE

Department of Neurology and NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin

eingeladener Redner

24/03/2023
16:45 – 17:00 15 Min. 0 Min.
Vortrag
Moderne Therapieoptionen in der Behandlung der Myasthenia gravis

Speaker

22/03/2023
Poster
P 103
Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized Myasthenia Gravis –interim results of the ADAPT+ study
Therapie

Further involvements

22/03/2023
Poster
P 86
Beyond complement - proteometabolomics identify the versatile consequences of eculizumab treatment in myasthenia gravis
Pathophysiologie und molekulare Mechanismen, Therapie
22/03/2023
Poster
P 63
Komplementablagerungen an der neuromuskulären Endplatte bei LRP4-positiver Myasthenia gravis
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen
22/03/2023
Poster
P 93
Efficacy of ravulizumab in generalized myasthenia gravis according to time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study
Therapie
22/03/2023
Poster
P 103
Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized Myasthenia Gravis –interim results of the ADAPT+ study
Therapie
24/03/2023
15:50 – 15:55 4 Min. 1 Min.
Orales Poster
P 63
Komplementablagerungen an der neuromuskulären Endplatte bei LRP4-positiver Myasthenia gravis
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen
24/03/2023
16:10 – 16:15 4 Min. 1 Min.
Orales Poster
P 86
Beyond complement - proteometabolomics identify the versatile consequences of eculizumab treatment in myasthenia gravis
Pathophysiologie und molekulare Mechanismen, Therapie
24/03/2023
17:30 – 17:40 10 Min. 0 Min.
Freier Vortrag
FV 28
Proteomic profiling identifies ITIH3 as biomarker for disease activity in myasthenia gravis
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen